Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Articles|April 21, 2020
Join Pharmacy Times on Tuesday for the Webinar ‘The Value of the Pharmacist in Treating COVID-19’
Pharmacy Times® invites you to join us and experts in pharmacy to gain insight into the value pharmacists provide in treating patients throughout the pandemic.
Advertisement
Pharmacy Times® invites you to join us and experts in pharmacy to gain insight into the value pharmacists provide in treating patients throughout the coronavirus disease 2019 (COVID-19) pandemic. The Pharmacy Times® webinar “The Value of the Pharmacist in Treating COVID-19” will be held Tuesday, April 28 at 12 pm EDT.
Click to register for this complimentary webinar:
Join expert faculty members as they explore:
- Pharmacists' significant role in treating the outbreak
- Management of increased demand of services, home delivery and demand for drive-thru services
- Pharmacist COVID-19 testing authorization
- Reaching patients in rural areas and patients with limited mobility
- Technicians' role in meeting increased demands
- Staff safety measures and contingency plans in the event a team member is infected
- Innovations as a result of the pandemic
Advertisement
Related to this article
The data helps pharmaicts predict who will react strongly to mRNA vaccines—giving them a science-backed talking point during respiratory season.
At the 2026 New England Institute of Ambulatory Care Pharmacists (NEIAP) Annual Forum, Jennifer Goldman detailed how monitoring data drive engagement—and how a new dual sensor readies pharmacists for ketone alerts.
Carole R. Berini, PhD, and Saamir Pasha, MPH, of Ontada discuss a model designed to estimate missing baseline ECOG performance status in advanced prostate cancer and the validation needed before it can support broader real-world evidence research.
Findings presented at the European Respiratory Society Congress 2026 suggest semaglutide may offer respiratory benefits beyond its approved diabetes and obesity indications.
Ataxia-telangiectasia (A-T) is a rare neurodegenerative disorder that primarily affects the nervous system, causing progressive loss of muscle control and coordination.
Most patients screened by a hospital pharmacist-led transitions-of-care service had unmet pneumococcal and other vaccine needs, and most accepted vaccination when offered.
CDC-recommended adult vaccination programs for pneumococcal disease, RSV, influenza, and COVID-19 prevent over 182,000 deaths and generate up to $12 in societal value for every $1 spent.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Dapagliflozin in Heart Failure: Congestion Isn't the Gatekeeper
2
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
3
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
4
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
5